EcoDrugPlus

Cholecystokinin Receptor-Like

Ensembl ID : ENSSAUG00010004798
Gene Symbol: LOC115576982
3 Cross references
193 Possible Orthologues:

Cholecystokinin Receptor-Like

Ensembl ID : ENSSAUG00010014403
Gene Symbol: LOC115587467
2 Cross references
191 Possible Orthologues:

Cholesterol 24-Hydroxylase

Ensembl ID : ENSSAUG00010008481
Gene Symbol: LOC115573549
3 Cross references
258 Possible Orthologues:

Cholesteryl Ester Transfer Protein

Ensembl ID : ENSSAUG00010003279
Gene Symbol: CETP
3 Cross references
137 Possible Orthologues:

Cholinergic Receptor Muscarinic 3

Ensembl ID : ENSSAUG00010026767
Gene Symbol: CHRM3
3 Cross references
187 Possible Orthologues:

Cholinergic Receptor Muscarinic 3

Ensembl ID : ENSSAUG00010010846
Gene Symbol: CHRM3
1 Cross references
186 Possible Orthologues:

Cholinergic Receptor Muscarinic 4

Ensembl ID : ENSSAUG00010006031
Gene Symbol: CHRM4
3 Cross references
184 Possible Orthologues:

Cholinergic Receptor Muscarinic 5

Ensembl ID : ENSSAUG00010017632
Gene Symbol: CHRM5
3 Cross references
195 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 3 Subunit

Ensembl ID : ENSSAUG00010011757
Gene Symbol: CHRNA3
3 Cross references
202 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 2 Subunit

Ensembl ID : ENSSAUG00010019309
Gene Symbol: CHRNB2
3 Cross references
197 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 4 Subunit

Ensembl ID : ENSSAUG00010011754
Gene Symbol: CHRNB4
3 Cross references
193 Possible Orthologues:

Coagulation Factor Ii Thrombin Receptor

Ensembl ID : ENSSAUG00010005733
Gene Symbol: F2R
1 Cross references
258 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).